ki:elements Publishes New Validation Results on Remote Speech Biomarker for Cognition (SB-C) in Early Alzheimer's Disease

ki:elementsDigital speech biomarker company ki:elements has published validation results on the use of its ki:e speech biomarker for cognition (SB-C) in early Alzheimer’s disease in the "Karger - Digital Biomarkers" journal.(1)

Two European dementia studies - the Dutch DeepSpA study in collaboration with Maastricht University & the Scottish SPeAK study in collaboration with University of Edinburgh - helped to validate the psychometric properties of the SB-C. Results demonstrate the ki:e SB-C's ability to differentiate subjective complaints from people with mild cognitive impairment, and its ability to track decline towards Mild Cognitive Impairment in early phases of the disease within a year. On a construct level the SB-C score is correlated with established measures for cognition and its domain scores are anchored around established assessments for neurocognitive functions such as learning and memory, executive function and processing speed. In the longitudinal DeepSpA study the SB-C shows also good test-retest reliability. Validation followed the V3 approach championed by the Digital Medicine Society (DiMe).

Prof. Craig Ritchie, Chair of the Psychiatry of Ageing and Director of the Centre for Dementia Prevention at the University of Edinburgh, and PI of the SpEAK study commented: "Early detection of AD is the prerequisite for prevention. These results show that speech is a scalable and sensitive screening tool that could be a key building block in ending AD."

Dr. Johannes Tröger, Chief Scientific Officer of ki:elements added: "We are pleased with these validation results in early AD, validating that SB-C is a reliable measure of cognition - usable in clinical trials and healthcare. In parallel, we are working on studies validating the SB-C in even earlier, preclinical stages of the disease."

About ki:elements and SB-C

ki:elements GmbH is pioneering the research and development of novel digital speech biomarkers. The ki:e speech biomarker for cognition (SB-C) is a speech based cognitive digital biomarker that takes fifteen minutes to complete, can be administered remotely and automatically. It is used in academic and pharmaceutical research as a scalable cognition measurement and screening tool.

For more information, visit https://ki-elements.de

1. Tröger J, Baykara E, Zhao J, ter Huurne D, Possemis N, Mallick E, Schäfer S, Schwed L, Mina M, Linz N, Ramakers I, Ritchie C.
Validation of the Remote Automated ki:e Speech Biomarker for Cognition in Mild Cognitive Impairment: Verification and Validation following DiME V3 Framework.
Digit Biomark 2022;6:107-116. doi: 10.1159/000526471

Most Popular Now

Giving Doctors an AI-Powered Head Start …

Detection of melanoma and a range of other skin diseases will be faster and more accurate with a new artificial intelligence (AI) powered tool that analyses multiple imaging types simultaneously...

AI Medical Receptionist Modernizing Doct…

A virtual medical receptionist named "Cassie," developed through research at Texas A&M University, is transforming the way patients interact with health care providers. Cassie is a digital-human assistant created by Humanate...

Using Data and AI to Create Better Healt…

Academic medical centers could transform patient care by adopting principles from learning health systems principles, according to researchers from Weill Cornell Medicine and the University of California, San Diego. In...

Northern Ireland Completes Nationwide Ro…

Go-lives at Western and Southern health and social care trusts mean every pathology service is using the same laboratory information management system; improving efficiency and quality. An ambitious technology project to...

AI Detects Hidden Heart Disease Using Ex…

Mass General Brigham researchers have developed a new AI tool in collaboration with the United States Department of Veterans Affairs (VA) to probe through previously collected CT scans and identify...

AI Tool Set to Transform Characterisatio…

A multinational team of researchers, co-led by the Garvan Institute of Medical Research, has developed and tested a new AI tool to better characterise the diversity of individual cells within...

Human-AI Collectives Make the Most Accur…

Diagnostic errors are among the most serious problems in everyday medical practice. AI systems - especially large language models (LLMs) like ChatGPT-4, Gemini, or Claude 3 - offer new ways...

MHP-Net: A Revolutionary AI Model for Ac…

Liver cancer is the sixth most common cancer globally and a leading cause of cancer-related deaths. Accurate segmentation of liver tumors is a crucial step for the management of the...

Highland Marketing Announced as Official…

Highland Marketing has been named, for the second year running, the official communications partner for HETT Show 2025, the UK's leading digital health conference and exhibition. Taking place 7-8 October...

Groundbreaking TACIT Algorithm Offers Ne…

Researchers at VCU Massey Comprehensive Cancer Center have developed a novel algorithm that could provide a revolutionary tool for determining the best options for patients - both in the treatment...

The Many Ways that AI Enters Rheumatolog…

High-resolution computed tomography (HRCT) is the standard to diagnose and assess progression in interstitial lung disease (ILD), a key feature in systemic sclerosis (SSc). But AI-assisted interpretation has the potential...